Neuroblastoma is a malignant tumor originating from undifferentiated neuroblasts, mainly occurring in infants and young children, especially those under 5 years old, and more commonly in infants and young children under 2 years old. This type of tumor is highly malignant and has a complex condition. Although the tumor boundary is clear, the texture is hard and often accompanied by bleeding, necrosis, or cystic changes. The incidence of neuroblastoma is closely related to genetic susceptibility factors, and there is a possibility of familial inheritance, but the vast majority of cases are not directly caused by genetic factors.

Clinical symptoms

The clinical symptoms of neuroblastoma vary depending on the location of tumor origin. Common symptoms include asthma, cough, diarrhea, abdominal distension, and constipation. Neuroblastoma originating from the adrenal gland may also cause increased heart rate and anxiety. In addition, some patients may experience eye symptoms, skin symptoms, and paraneoplastic syndrome.

therapeutic method

The treatment of neuroblastoma is a multidisciplinary collaborative process, mainly including the following methods:

Surgical resection is one of the main treatment methods for neuroblastoma, especially effective for localized lesions. Surgery should be determined based on a comprehensive evaluation of the patient's age, physical condition, and tumor metastasis.

Chemotherapy: Using chemical drugs to kill tumor cells in the body, suitable for widely distributed neuroblastoma to control micro metastases and primary lesions. Common medications include cyclophosphamide, doxorubicin, carboplatin, etc.

Radiotherapy: The use of radiation to kill or inhibit tumor cell growth, suitable for locally advanced or unresectable cases, can reduce tumor volume for subsequent surgical intervention.

Biological targeted therapy: Targeting neuroblastoma with specific gene mutations, drugs targeting specific molecular abnormalities are used for treatment, which can accurately strike malignant cells without harming innocent tissues.

Immunotherapy: Fighting cancer by enhancing the body's own anti-tumor immunity, including monoclonal antibodies, CAR-T cell therapy, etc. For recurrent or refractory neuroblastoma, immunotherapy can be used as a supplementary or alternative approach.

Autologous stem cell transplantation: Internationally, two consecutive rounds of autologous hematopoietic stem cell transplantation have achieved certain results, but currently it is not the standard treatment plan and needs to be determined based on the doctor's evaluation.

prognosis

The prognosis of neuroblastoma varies depending on factors such as patient age, stage, and treatment plan. Low to medium risk patients have a better prognosis, while high-risk populations have a poorer prognosis. Overall, the five-year survival rate of neuroblastoma is only about 20%, so early detection, timely intervention, and comprehensive treatment are crucial for improving the survival rate and quality of life of patients.

The above information is for reference only. The specific treatment plan should be formulated by the doctor according to the patient's specific situation. If you have any questions or discomfort, please seek medical advice promptly from a professional doctor.